Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -26% | -25.6% | 31% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.2% | 68.8% | 68.7% | 56.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -38.6% | -36.7% | -40.2% | -84.1% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -57.9% | -54.8% | -97.7% | -131.4% |
| EPS | -0.11 | -0.15 | -0.39 | -0.43 |
| % Growth | 26.7% | 61.5% | 9.3% | – |
| EPS Diluted | -0.11 | -0.15 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -31.6% | -30.9% | -35.9% | -138.9% |